# Olaparib in People With Malignant Mesothelioma

> **NCT03531840** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 23 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Olaparib
- **DEVICE:** ClinOmics

## Key facts

- **NCT ID:** NCT03531840
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-11
- **Primary completion:** 2019-12-04
- **Final completion:** 2020-10-21
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531840, "Olaparib in People With Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03531840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*